MURA (Mural Oncology) EBIT per Share : $-8.15 (TTM As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Mural Oncology EBIT per Share?

Mural Oncology's EBIT per Share for the three months ended in Dec. 2024 was $-2.10. Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 was $-8.15.

During the past 3 years, the average EBIT per Share Growth Rate was 8.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Mural Oncology's EBIT per Share or its related term are showing as below:

MURA' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: 8.1 Med: 8.1 Max: 8.1
Current: 8.1

During the past 4 years, the highest 3-Year average EBIT per Share Growth Rate of Mural Oncology was 8.10% per year. The lowest was 8.10% per year. And the median was 8.10% per year.

MURA's 3-Year EBIT Growth Rate is ranked better than
55.39% of 1224 companies
in the Biotechnology industry
Industry Median: 4.2 vs MURA: 8.10

Mural Oncology's EBIT for the three months ended in Dec. 2024 was $-35.85 Mil.

Mural Oncology EBIT per Share Historical Data

The historical data trend for Mural Oncology's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Mural Oncology EBIT per Share Chart

Mural Oncology Annual Data

Trend

Dec21

Dec22

Dec23

Dec24

EBIT per Share

-10.51

-11.08

-11.76

-8.16

Mural Oncology Quarterly Data
	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
EBIT per Share	Get a 7-Day Free Trial							-3.51	-2.03	-2.03	-2.00	-2.10

Mural Oncology EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Mural Oncology's EBIT per Share for the fiscal year that ended in Dec. 2024 is calculated as

	EBIT per Share		(A: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-138.262	/	16.955
=	-8.15

Mural Oncology's EBIT per Share for the quarter that ended in Dec. 2024 is calculated as

	EBIT per Share		(Q: Dec. 2024 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-35.854	/	17.070
=	-2.10

EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.15

Mural Oncology (NAS:MURA) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Mural Oncology EBIT per Share Related Terms

Thank you for viewing the detailed overview of Mural Oncology's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Mural Oncology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Mural Oncology PLC (NAS:MURA) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 Earlsfort Terrace, Dublin 2, Dublin, IRL, D02 T380

Website

https://www.muraloncology.com

Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.